Alpha Cognition

About Alpha Cognition

Alpha Cognition Inc. (ACI) is a biotechnology company specializing in the development of innovative therapies for neurological diseases. The company primarily targets conditions affecting the central nervous system, leveraging its expertise in cell growth, survival, repair, and inflammation. ACI's core product pipeline includes therapies that promote cell survival and regulate inflammatory processes, with a significant focus on lysosomal function and microglial responses to disease. The company operates in the biopharmaceutical market and serves patients suffering from neurological disorders, healthcare providers, and potential licensing partners. ACI's business model revolves around the research, development, and out-licensing of its therapeutic assets to third parties. Revenue is generated through licensing agreements, milestone payments, and potential royalties from commercialized products. The company is currently anticipating FDA approval for its lead product in mid-2024, which marks a significant milestone in its regulatory journey. Key personnel include Denis Kay, MSc, PhD, Chief Scientific Officer, with over 30 years of experience in neurological disease research, and Don Kalkofen, BA, Chief Financial Officer, with two decades of financial leadership in public and private companies. Keywords: biotechnology, neurological diseases, cell survival, inflammation, central nervous system, lysosomal function, microglial responses, FDA approval, out-licensing, therapeutic assets.